XSHG
688098
Market cap515mUSD
Oct 09, Last price
8.32CNY
1D
-1.07%
1Q
-9.07%
IPO
-68.96%
Name
Shanghai Shen Lian Biomedical Corp
Chart & performance
P/E
—
P/S
11.85
EPS
—
Div yield, %
0.42%
Shrs. gr., 5y
-1.78%
Rev. gr., 5y
-3.12%
Revenues
288m
-4.99%
Net income
-19m
L-57.33%
CFO
33m
-62.99%
Dividend
Jun 14, 20240.035 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Shen Lian Biomedical Corporation operates within China's animal health industry, specializing in the entire lifecycle of veterinary biological products, from initial research and development to manufacturing and sales. A primary focus for the company is the creation of advanced synthetic peptide vaccines, specifically engineered to combat foot-and-mouth disease. This enterprise was established in 2001 and is based in Shanghai, China.
Key people
Dongsheng Nie
Chairman of the Board · since 2006
Bo Yin
Chief Technology Officer · since 2023
Zhen Zhang
General Manager · since 2024
Wenhao Nie
Deputy General Manager, Director · since 2022
Haixia Yu
Secretary of the Board · since 2023
Eudes Fabre
Director · since 2024
Guangzhi Tong
Director · since 2024
Congzhou Yang
Director · since 2022
Zhiqiang Yang
Director · since 2024
Jianjun Li
Independent Director · since 2021
Independent Director · since 2024
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||